Kenny Weng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Kenny Weng has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Himisha Beltran
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
39 shared publications - Varadha Balaji Venkadakrishnan
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
39 shared publications - Adam Presser
Department of Medical Oncology Dana-Farber Cancer Institute Boston MA USA
29 shared publications - Andres Martin Acosta
Department of Pathology, Indiana University, Indianapolis, USA
29 shared publications - Francisca Vazquez
Broad Institute of MIT and Harvard, Cambridge, USA
29 shared publications - James Neiswender
The Broad Institute of MIT and Harvard Cambridge MA USA
29 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers
Loss of RB across cancer types
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Significance of RB Loss in Unlocking Phenotypic Plasticity in Advanced Cancers
Loss of RB across cancer types
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Supplementary data and supplementary figure legends
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Supplementary data and supplementary figure legends
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Figure S5 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Figure S5 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Figure S7 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Figure S7 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Figure S2 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Figure S2 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Figure S1 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Figure S1 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Figure S4 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Figure S4 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Figure S6 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Figure S6 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Cover Art from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
An abstract representation of transcription factor synergy in the lineage reprogramming of neuroendocrine prostate cancer.
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessCover Art from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
An abstract representation of transcription factor synergy in the lineage reprogramming of neuroendocrine prostate cancer.
- Open Access
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Figure S3 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
- 23 October 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression
Figure S3 from Epigenetic Derepression of PROX1 Promotes Neuroendocrine Prostate Cancer Progression